. 2021 Apr 19;6(3):100103. doi: 10.1016/j.esmoop.2021.100103

Table 2.

Prospective, organoid-informed treatment of patients in the SENSOR trial

Drug	Patient	Baseline			First response evaluation			End of treatment
Drug	Patient	Sum of RECIST lesions in mm	Biopsied lesion in mm	CEA (ng/ml)	Sum of RECIST lesions in mm (% relative to baseline)	Biopsied lesion in mm (% relative to baseline)	CEA (ng/ml)	Days after start treatment	Reason for end of treatment
Vistusertib	P1	101	30	253	107 (+6%)	29 (−3%)	1165	58	New symptomatic brain metastases
	P2	110	21	648	123 (+12%)	22 (+5%)	727	107	Progressive disease
	P2	110	21	648	132 (+20%)^a	26 (+24%)^a	1119^a	107	Progressive disease
	P3	300	9	923	351 (+17%)	11 (+22%)	652	57	New lesions at response evaluation
Capivasertib	P4	67			91 (+35%)			52	Progressive disease
	P5	46	22		47 (+2%)	25 (+14%)		20	Clinical progression
	P6	234	81	359	245 (+5%)	89 (+10%)	514	20	New symptomatic brain metastases

Response to experimental treatment was evaluated using RECIST 1.1 every 2 months. When available, the response in the biopsied lesion and levels of CEA (in ng/ml) were also recorded. Clinical disease progression was observed for patients P5 and P6 before the first response evaluation. The tumor measurements and CEA levels at first response evaluation correspond with the CT scan and blood withdrawal for clinical purposes, on day 20 after start of treatment of both patients.

CEA, cancer embryonic antigen; CT, computed tomography.

Second evaluation.